Associate Professor Jemma Hopewell
|Tel||+44 (0)1865 743661|
- Genetic epidemiology of Lp(a), kidney function and vascular disease Research Group
- Using population biobanks and pharmacogenomics to enhance clinical trial design Research Group
- Investigating genetic and non-genetic determinants of heart rhythm Research Group
- Genetic determinants of chronic kidney disease and vascular risk Research Group
BSc (Hons) MSc PhD (Cantab)
Associate Professor & Senior Scientist in Genetic Epidemiology and Clinical Trials
- BHF Intermediate Basic Science Research Fellow
- MSc in Global Health Science Module Lead: Genetic Epidemiology
Jemma is a senior scientist leading a genetic epidemiology and statistics team in a programme of research focusing on pharmacogenomics, cardiovascular genetic epidemiology, and clinical trial-based studies. She has particular interests in determining predictors of patient response to cardiovascular therapies such as statins, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of risk factors for vascular disease such as Lp(a). Her research involves CTSU's vascular mega-trials, large-scale biobank studies, and international consortia, for which she also serves on various Steering and Analysis Committees. In addition, she leads the Genetic Epidemiology module for the MSc in Global Health Science.
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation.
Christophersen IE. et al, (2017), Nat Genet, 49, 946 - 952
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190
No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis.
Loley C. et al, (2016), Sci Rep, 6, 35278 - 35278
The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs
Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes
Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration.
Malik R. et al, (2016), Neurology, 86, 1217 - 1226